RT Journal Article
SR Electronic
T1 A system-view of <em>B. pertussis</em> booster vaccine responses in adults primed with whole-cell vs. acellular vaccine in infancy
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.05.15.098830
DO 10.1101/2020.05.15.098830
A1 da Silva Antunes, Ricardo
A1 Pomaznoy, Mikhail
A1 Soldevila, Ferran
A1 Babor, Mariana
A1 Bennett, Jason
A1 Tian, Yuan
A1 Khalil, Natalie
A1 Qian, Yu
A1 Mandava, Aishwarya
A1 Scheuermann, Richard H.
A1 Cortese, Mario
A1 Pulendran, Bali
A1 Petro, Christopher D.
A1 Gilkes, Adrienne
A1 Purcell, Lisa A.
A1 Sette, Alessandro
A1 Peters, Bjoern
YR 2020
UL http://biorxiv.org/content/early/2020/05/16/2020.05.15.098830.abstract
AB Whole-cell inactivated vaccine against Bordetella pertussis (wP) was substituted in many countries by an acellular subunit vaccine (aP) to reduce side effects. Recent epidemiological studies have shown that aP vaccination in infancy induces less durable immunity than wP vaccination. To determine immunological differences associated with aP vs. wP priming, we performed system-level profiling of the immune response in adults primed with aP vs. wP vaccine in infancy following the Tdap booster vaccination as a surrogate to antigen encounter in vivo. Shared immune responses across cohorts were identified, including an increase of the blood monocyte frequency on day 1, and strong antigen-specific IgG response seven days after boost. Comparing aP and wP primed individuals, we found a subset of aP-primed individuals with higher levels of expression for several genes including CCL3 on day 3 and NFKBIA and ICAM1 on day 7 post immunization. These observations were supported by increased CCL3 concentrations in plasma of aP primed individuals. Contrary to the wP individuals, the CCL3-high aP subset presented boosted PT-specific IgE responses. Furthermore, higher antigen specific IgG4 and IgG3 antibodies against specific vaccine antigens at baseline and post boost of aP individuals was observed, suggesting a long term maintained difference in the IgG subtype response. Overall our findings demonstrate that, while broad immune response patterns to Tdap boost overlap between aP and wP primed individuals, a subset of aP primed individuals present a divergent response. These findings provide candidate targets to study the causes and correlates of waning immunity after aP vaccination.Competing Interest StatementA.G., C.D.P. and L.A.P. are employees and shareholders of Regeneron Pharmaceuticals, Inc.